Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961498 | 0.85 | DAO (0.57) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL6598156 | 0.85 | ALDH1A1 (0.53) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL21169605 | 0.85 | NPC1 (0.57) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL359532 | 0.81 | NPC1 (0.53) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL4375850 | 0.81 | NPC1 (0.57) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL1721002 | 0.81 | NPC1 (0.57) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL507149 | 0.81 | ALDH1A1 (0.58) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL30586439 | 0.81 | ALDH1A1 (0.58) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL19338490 | 0.81 | NPC1 (0.57) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL4075213 | 0.81 | NPC1 (0.57) | NPC1POLBRAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5459150-A | Treatment of allergies and inflammatory diseases | ABBOTT LABORATORIES (US) | 1995-10-17 | — | — | US | claimed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
| US-8158362-B2 | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype | DECODE GENETICS EHF. (IS) | 2012-04-17 | — | — | US | disclosed |
| US-7851486-B2 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2010-12-14 | — | — | US | disclosed |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | DECODE GENETICS EHF. (IS) | 2010-08-26 | — | — | US | disclosed |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | DECODE GENETICS EHF. (IS) | 2008-11-27 | — | — | US | disclosed |
| US-20050282855-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2005-12-22 | — | — | US | disclosed |
| EP-1579010-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005075022-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2005-08-18 | — | — | WO | disclosed |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | DECODE GENETICS EHF. (IS) | 2005-05-26 | — | — | US | disclosed |
| WO-2004035741-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2004-04-29 | — | — | WO | disclosed |
| EP-1385833-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Amgen Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6642255-B2 | Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| EP-1355648-A2 | 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a) | Bristol-Myers Squibb Pharma Company (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002055491-A2 | 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a) | BRISTOL MYERS SQUIBB COMPANY P (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | NPC1 1062/4885POLB 539/4885RAB9A 4775/4885 |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | ALOX15B, ALOX15, ALOX5 | NPC1 2179/4885POLB 1741/4885RAB9A 1992/4885 |
| US-20080293750-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment | PLAAT3, PLAAT2, PLA2G7 | NPC1 3521/4885POLB 1810/4885RAB9A 3102/4885 |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | ALOX5, ALOX15, ALOX12 | NPC1 4682/4885POLB 251/4885RAB9A 4192/4885 |
| US-20050282855-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | PLAAT3, PLAAT2, PLA2G7 | NPC1 4149/4885POLB 897/4885RAB9A 3091/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | NPC1 1062/4885POLB 539/4885RAB9A 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.